[PR Newswire] - SAN DIEGO, Nov. 8, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), a pharmaceutical company focused on commercializing novel drug formulations invented by physicians and pharmacists through their clinical experience with patients, today announced that it will be attending the 117th Annual Meeting of the American Academy of Ophthalmology (AAO) in New Orleans, November 16-19 (Booth #5058). Imprimis' presence at this conference is primarily to continue the pre-launch assessments of two of its proprietary ophthalmic sterile injectable compounded formulations, which Imprimis expects to make available to the ophthalmology community in 2014. Imprimis will also be hosting two events, during which they will be soliciting feedback from the ophthalmology community regarding the utility and commercialization potential of its proprietary ophthalmic compounded formulations. To schedule meetings with Imprimis or to attend an Imprimis sponsored event, please contact Forest Flodin, Director of Corporate Development, at fflodin@imprimispharma.com.
No comments:
Post a Comment